Biophytis second AGM to take place on May 28, 2020 without the physical
presence of its shareholders
Paris (France), Cambridge (Massachusetts, USA), May 20, 2020, 8:00 a.m. CEST -
BIOPHYTIS (Euronext Growth Paris: ALBPS) a clinical-stage biotechnology company
specialized in the development of drug candidates for treatment of aged related
diseases, amongst which neuromuscular diseases, informs its shareholders that
the second combined General Meeting will be held on May 28, 2020 2020 at 11 am.
at the offices of Reed Smith LLP, 112 avenue Kléber, 75016 Paris.
As a result of restrictions placed on the movement and gatherings of persons
due to the COVID-19 pandemic, the Company's Combined General Meeting will be
held behind closed doors without the physical presence of its shareholders, in
accordance with the provisions of Article 4 of Order no. 2020-321 of March
The notice of meeting, comprising the agenda and the draft resolutions was
published in the French official legal bulletin Bulletin des Annonces Légales
Obligatoires (BALO) n° 60. These notices include information on how to attend
and vote at the General Meeting, as well as the vote bulletin.
All of the documents regarding this combined General Meeting are available to
shareholders on the Company's website: www.biophytis.com, in the section
Investors / General Assembly 2020:
Shareholders are strongly encouraged to vote in advance of the shareholder
meeting by mail, by appointing the Chairman of the meeting as your proxy or via
the secure online platform VOTEACCESS.
On account of the possible effect of the Covid-19 pandemic on postal delivery
times, it is recommended to return your voting forms as soon as practicable.
Please note that the voting forms should be submitted no later than :
- For postal votes, the statutory deadlines apply :
o May 24 (4-day deadline before the Meeting) for issuing instructions to the
o May 25 (3-day deadline before the Meeting) for appointing the proxy
- VOTEACCESS :
o May 27 at 3 p.m. CEST
The vote of shareholders who submitted their vote via the post, email or the
Internet for the first general meeting remains valid and counted for the
general meeting on the second call.
Shareholders who did not vote by post or proxy as part of the first combined
General Meeting will be invited to send their forms and shareholder
(i) By post : CACEIS Corporate Trust, Service Assemblées Générales
Centralisées - 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX
Cedex 9, or
(ii) via email: email@example.com
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, especially
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of BIO101 is being
developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company
plans to start the clinical development in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus). The Company has received approval from the Belgian Regulatory
Authority (FAMHP) to begin the Phase 2/3 clinical trial (COVA) with Sarconeos
(BIO101), evaluating it as a potential treatment for respiratory failure
associated with Covid-19. The Company also filed clinical trial applications
with the FDA in the US, MHRA in the UK and the French regulatory agency, ANSM
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS - ISIN: FR0012816825).
For more information www.biophytis.com.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO